Quest for the right Drug
מינירין טבליות 0.2 מ"ג MINIRIN TABLETS 0.2 MG (DESMOPRESSIN ACETATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and Method of Administration Central Diabetes Insipidus: Tablets administration. A suitable initial dose for children and adults is 0.1 mg three times daily. The dose is than adjusted according to the response of the patient. The average daily dose is between 0.2 and 1.2 mg with tablet administration. For most patients, 0.1 – 0.2 mg three times daily is the optimal dose regimen. Nocturnal Enuresis: Tablets administration. A suitable initial dose is 0.2 mg at bedtime. The dose may be increased up to 0.4 mg if the lower dose is not sufficiently effective. If treatment continues over the long-term, a treatment-free week should be introduced every three months, in order to ascertain whether the condition has resolved spontaneously. If the desired clinical effect has not been achieved after 4 weeks of dose titration, treatment should be discontinued. Nocturia: The recommended initial dose is 0.1 mg at bedtime. If this does is not sufficiently effective after one week it can be increased to 0.2 mg and then to 0.4 mg by means of weekly increases. Fluid restriction is to be enforced. In nocturic patients, a frequency/volume chart should be used to diagnose nocturnal polyuria for at least 2 days and nights before starting treatment. A night-time urine production exceeding the functional bladder capacity or exceeding 1/3 of the 24-hour urine production is regarded as nocturnal polyuria. Serum sodium must be measured before beginning the treatment and 3 days after initiation or increase in dosage and other times during treatment as seemed necessary by the treating physician. If adequate medical effect is not achieved within 4 weeks following appropriate dose titration the medication should be discontinued. Assessment of the necessity of continued treatment should be made after three months during one drug- free week. Fluid restriction should be observed, (see Special Warnings and Special Precautions for use). In the event of signs of water retention/hyponatraemia treatment should be interrupted.
שימוש לפי פנקס קופ''ח כללית 1994
Short term treatment of primary nocturnal enuresis (patients over 5 years who have the ability to concentrate urine)
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף